Investigation of the efficacy and tolerability of Dr Michaels(R) (also branded as Eczitinex(R) and Itchinex Eczitinex(R)) topical products in the treatment of atopic dermatitis in children

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F16%3A10375023" target="_blank" >RIV/00216208:11130/16:10375023 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Investigation of the efficacy and tolerability of Dr Michaels(R) (also branded as Eczitinex(R) and Itchinex Eczitinex(R)) topical products in the treatment of atopic dermatitis in children

Popis výsledku v původním jazyce

Atopic eczema is a chronic relapsing inflammatory skin disorder, characterized clinically by intensely pruritic eczematous skin lesions and a defective epidermal barrier. It affects more than 15% of children and up to 10%of adults, which makes the disease a social health problem still without a challenging treatment. The aim of this study was to evaluate the efficacy and tolerability of Dr Michaels(R) (Eczitinex(R)) topical product family in the treatment of atopic dermatitis in children. We studied a group of 30 patients (17 female, 13 male), aged 5 to 13 (mean age: 9), affected by atopic dermatitis since they were newborn. All patients had been unsuccessfully treated with conventional anti-inflammatory therapies and ceased treatment 2 weeks before commencing research. The patients were treated with Dr Michaels(R) (Eczitinex(R) and Itchinex(R)) product family including a moisturising bar, topical ointment and PSC 900 oral herbal formulation. The treatment was evaluated clinically and photographically at 0, 1, 2, 4, 6, 8, 10, 12, and 14 weeks. Twenty-eight patients showed a significant improvement of cutaneous rashes and pruritus on the first week of treatment, with a complete remission at 10-12 weeks. Only two patients, brother and sister respectively, showed a slow response to treatment and reported an increasing itching. Following 14 weeks of treatment with the Dr Michaels(R) (Eczitinex(R) and Itchinex(R)) product family, patients demonstrated complete resolution of their AD. All patients showed a marked improvement in their condition within 3 days of treatment with most of the lesions and symptoms totally resolved within 10 to 12 weeks of treatment with Dr Michaels(R) (Eczitinex(R) and Itchinex(R)) family of products. This clinical report highlights that the Dr Michaels(R) (Eczitinex(R) and Itchinex(R)) product family is a safe and effective treatment option for AD.

Název v anglickém jazyce

Investigation of the efficacy and tolerability of Dr Michaels(R) (also branded as Eczitinex(R) and Itchinex Eczitinex(R)) topical products in the treatment of atopic dermatitis in children

Popis výsledku anglicky

Atopic eczema is a chronic relapsing inflammatory skin disorder, characterized clinically by intensely pruritic eczematous skin lesions and a defective epidermal barrier. It affects more than 15% of children and up to 10%of adults, which makes the disease a social health problem still without a challenging treatment. The aim of this study was to evaluate the efficacy and tolerability of Dr Michaels(R) (Eczitinex(R)) topical product family in the treatment of atopic dermatitis in children. We studied a group of 30 patients (17 female, 13 male), aged 5 to 13 (mean age: 9), affected by atopic dermatitis since they were newborn. All patients had been unsuccessfully treated with conventional anti-inflammatory therapies and ceased treatment 2 weeks before commencing research. The patients were treated with Dr Michaels(R) (Eczitinex(R) and Itchinex(R)) product family including a moisturising bar, topical ointment and PSC 900 oral herbal formulation. The treatment was evaluated clinically and photographically at 0, 1, 2, 4, 6, 8, 10, 12, and 14 weeks. Twenty-eight patients showed a significant improvement of cutaneous rashes and pruritus on the first week of treatment, with a complete remission at 10-12 weeks. Only two patients, brother and sister respectively, showed a slow response to treatment and reported an increasing itching. Following 14 weeks of treatment with the Dr Michaels(R) (Eczitinex(R) and Itchinex(R)) product family, patients demonstrated complete resolution of their AD. All patients showed a marked improvement in their condition within 3 days of treatment with most of the lesions and symptoms totally resolved within 10 to 12 weeks of treatment with Dr Michaels(R) (Eczitinex(R) and Itchinex(R)) family of products. This clinical report highlights that the Dr Michaels(R) (Eczitinex(R) and Itchinex(R)) product family is a safe and effective treatment option for AD.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Biological Regulators and Homeostatic Agents

ISSN

0393-974X

e-ISSN

—

Svazek periodika

30

Číslo periodika v rámci svazku

2 Suppl 3

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

9

Strana od-do

55-63

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85044153122